Eli Lilly Corporate Integrity Agreement

On January 15, 2009, assistant Attorney General for the Civil Division and Acting United States Attorney announced in Philadelphia a criminal investigation and civil transaction involving the pharmaceutical company Eli Lilly and Company. The case includes the off-label marketing of Eli Lilly drug Zyprexa for applications other than what the Food and Drug Administration has approved. The company is accused of selling poorly stigmatized drugs with inadequate employment instructions. A plea signed by Eli Lilly admits the company`s guilt in the criminal charge for false fire. In particular, Eli Lilly admits that between September 1999 and March 31, 2001, the company encouraged Zyprexa in older populations as a treatment for dementia, including Alzheimer`s dementia. Eli Lilly agreed to pay a $515 million fine and pay $100 million in additional assets. A civil agreement has been reached between Eli Lilly, U.S., and Relators, in which Eli Lilly will provide up to $800 million to the federal and state governments to resolve claims by Medicaid and other federal programs and agencies such as TRICARE, the Federal Health Workers Program, the Department of Veterans Affairs, the Bureau of Prisons and Health Assistance Utilities. The federal government will receive approximately $438 million from the civil colony. The national Medicaid programs and the District of Columbia will share up to $361 million in the civil colony, depending on the number of states participating in the colony. The Qui tam relators receive $78 million from the federal government in the amount of the transaction. An Enterprise Integrity Agreement (CIA) between Eli Lilly and the Office of Inspector General of the Department of Health and Human Services requires a board committee to review the company`s compliance program annually and certify its effectiveness; Some managers certify each year that their divisions or functional areas are compliant; That Eli Lilly send a letter to doctors informing them of global regulations; and that the company publish on its website information on payments to doctors such as fees, travel or accommodation. Eli Lilly is subject to exclusion from federal health programs, including Medicare and Medicaid, due to a substantial violation of the CIA, and will be fined for lesser offenses. Below is an alphabetical list of the major pharmaceutical and medical device manufacturer, concluded with the Office of the Inspector General (OIG) for the United States.

シェアする

  • このエントリーをはてなブックマークに追加